2 reports of this reaction
4.4% of all ALUMINUM ZIRCONIUM PENTACHLOROHYDREX GLY reports
#5 most reported adverse reaction
SKIN LESION is the #5 most commonly reported adverse reaction for ALUMINUM ZIRCONIUM PENTACHLOROHYDREX GLY, manufactured by The Procter & Gamble Manufacturing Company. There are 2 FDA adverse event reports linking ALUMINUM ZIRCONIUM PENTACHLOROHYDREX GLY to SKIN LESION. This represents approximately 4.4% of all 45 adverse event reports for this drug.
Patients taking ALUMINUM ZIRCONIUM PENTACHLOROHYDREX GLY who experience skin lesion should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SKIN LESION is moderately reported among ALUMINUM ZIRCONIUM PENTACHLOROHYDREX GLY users, representing a notable but not dominant share of adverse events.
In addition to skin lesion, the following adverse reactions have been reported for ALUMINUM ZIRCONIUM PENTACHLOROHYDREX GLY:
The following drugs have also been linked to skin lesion in FDA adverse event reports:
SKIN LESION has been reported as an adverse event in 2 FDA reports for ALUMINUM ZIRCONIUM PENTACHLOROHYDREX GLY. This does not prove causation, but indicates an association observed in post-market surveillance data.
SKIN LESION accounts for approximately 4.4% of all adverse event reports for ALUMINUM ZIRCONIUM PENTACHLOROHYDREX GLY, making it a notable side effect.
If you experience skin lesion while taking ALUMINUM ZIRCONIUM PENTACHLOROHYDREX GLY, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.